[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650306":3},{"organization":4,"armGroups":7,"interventions":36,"overallOfficials":51,"centralContacts":55,"locations":63,"responsibleParty":75,"collaborators":77,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":42,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":42,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":42,"overallStatus":101,"whyStopped":42,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"NYU Langone Health","OTHER",[8,16,20,24,28,32],{"label":9,"type":10,"description":11,"interventionNames":12},"Aspirin, then Clopidogrel, then Placebo","EXPERIMENTAL","Each subject will take an aspirin 81mg capsule daily for 4 weeks. After a washout period of 4 weeks, they will take the clopidogrel 75mg capsule daily for 4 weeks. After a second washout period of 4 weeks, they will take the Placebo capsule daily for 4 weeks.",[13,14,15],"Drug: Aspirin","Drug: Clopidogrel","Other: Placebo",{"label":17,"type":10,"description":18,"interventionNames":19},"Aspirin, then Placebo, then Clopidogrel","Each subject will take an aspirin 81mg capsule daily for 4 weeks. After a washout period of 4 weeks, they will take the Placebo capsule daily for 4 weeks. After a second washout period of 4 weeks, they will take the clopidogrel 75mg capsule daily for 4 weeks.",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Clopidogrel, then Aspirin, then Placebo","Each subject will take will take the clopidogrel 75mg capsule daily for 4 weeks. After a washout period of 4 weeks, they will take an aspirin 81mg capsule daily for 4 weeks. After a second washout period of 4 weeks, they will take the Placebo capsule daily for 4 weeks.",[13,14,15],{"label":25,"type":10,"description":26,"interventionNames":27},"Clopidogrel, then Placebo, then Aspirin","Each subject will take will take the clopidogrel 75mg capsule daily for 4 weeks. After a washout period of 4 weeks, they will take the Placebo capsule daily for 4 weeks. After a second washout period of 4 weeks, they will take an aspirin 81mg capsule daily for 4 weeks.",[13,14,15],{"label":29,"type":10,"description":30,"interventionNames":31},"Placebo, then Aspirin, then Clopidogrel","Each subject will take will take the Placebo capsule daily for 4 weeks. After a washout period of 4 weeks, they will take an aspirin 81mg capsule daily for 4 weeks. After a second washout period of 4 weeks, they will take the clopidogrel 75mg capsule daily for 4 weeks.",[13,14,15],{"label":33,"type":10,"description":34,"interventionNames":35},"Placebo, then Clopidogrel, then Aspirin","Each subject will take will take the Placebo capsule daily for 4 weeks. After a washout period of 4 weeks, they will take the clopidogrel 75mg capsule daily for 4 weeks. After a second washout period of 4 weeks, they will take an aspirin 81mg capsule daily for 4 weeks.",[13,14,15],[37,43,47],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"DRUG","Aspirin","81 mg capsule orally once daily for 4 weeks",[9,17,21,25,29,33],null,{"type":38,"name":44,"description":45,"armGroupLabels":46,"otherNames":42},"Clopidogrel","75 mg capsule orally once daily for 4 weeks",[9,17,21,25,29,33],{"type":6,"name":48,"description":49,"armGroupLabels":50,"otherNames":42},"Placebo","Matching placebo (microcellulose powder) capsule orally once daily for 4 weeks",[9,17,21,25,29,33],[52],{"name":53,"affiliation":5,"role":54},"Michael Garshick, MD","PRINCIPAL_INVESTIGATOR",[56,60],{"name":53,"role":57,"phone":58,"phoneExt":42,"email":59},"CONTACT","212-263-8032","Michael.Garshick@nyulangone.org",{"name":61,"role":57,"phone":42,"phoneExt":42,"email":62},"Sarah Boyce","Sarah.Boyce@nyulangone.org",[64],{"facility":5,"status":42,"city":65,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":42},"New York","10016","United States","US",{"type":70,"coordinates":71},"Point",[72,73],-74.00597,40.71427,{"lat":73,"lon":72},{"type":76,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR",[78],{"name":79,"class":80},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100650306","phase-4-a-clinical-trial-of-antiplatelets-in-psoriasis-100650306",false,"NCT07744191","A Clinical Trial of Antiplatelets in Psoriasis","A Randomized, Double-blind, Placebo-controlled Crossover Trial of Antiplatelet Therapies in Psoriasis","Inclusion Criteria:\n\n1. One of the following:\n\n   1. A history of psoriasis as confirmed by a board-certified dermatologist OR\n   2. A history of psoriatic arthritis as confirmed by a board-certified rheumatologist\n2. Age ≥ 18 \\& \\\u003C 90 years\n3. Able and willing to provide written informed consent for the study\n4. English-speaking unless a translated informed consent form is approved\n5. No previous antiplatelet or anticoagulant use for 14 days prior to enrollment\n\nExclusion Criteria:\n\n1. A prior history of a myocardial infarction, stroke\u002FTIA, or occlusive peripheral arterial disease\n2. Chronic antiplatelet\u002Fanticoagulant use that is not able to be stopped at least 14 days prior to study enrollment\n3. Uncontrolled hypertension resting systolic blood pressure \\> 180 mm Hg or diabetes HbA1c \\> 10%\n4. Known active cancer receiving treatment\n5. Pregnancy\n6. Anemia (hemoglobin \\\u003C 9 mg\u002Fdl) or thrombocytopenia (Platelet count \\\u003C75), or thrombocytosis (Platelet count \\>600)\n7. A history of severe bleeding or bleeding disorders\n8. Active gastrointestinal ulcer\n9. Active pathological bleeding.\n10. Chronic kidney disease (CrCl \\\u003C 30ml\u002Fmin)\n11. Congestive heart failure\n12. Known hypersensitivity to or allergy to aspirin, clopidogrel, or any of the components of the study capsules\n13. History of aspirin-exacerbated respiratory disease or asthma induced by salicylates or NSAIDs\n14. Currently breastfeeding\n15. Persons of childbearing potential unwilling to use acceptable contraception during the study","ALL","18 Years","90 Years",{"count":92,"type":93},60,"ESTIMATED","INTERVENTIONAL",[96],"PHASE4","The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more than aspirin or placebo. The primary endpoint is mean change in a composite endothelial pro-inflammatory\u002Fpro-atherosclerotic transcript expression signature measured from brachial vein endothelial cells.",[99,100],"Psoriasis (PsO)","Psoriatic Arthritis (PsA)","NOT_YET_RECRUITING","2026-08-03",{"date":104,"type":105},"2026-08-05","ACTUAL",{"date":107,"type":93},"2026-09",{"date":109,"type":93},"2031-09",{"name":5,"class":6},1]